Log in with your email address username.


[Correspondence] Questionable efficacy of the rVSV-ZEBOV Ebola vaccine – Authors’ reply

We thank Wolfram Metzger and Sarai Vivas-Martínez for expressing their concern about potential sources of bias in the final analysis of our ring vaccination trial of an rVSV-vectored vaccine for Ebola virus disease (rVSV-ZEBOV).1 In that trial, the point estimate of vaccine efficacy was 100%, with no confirmed cases of Ebola virus disease detected in vaccinated people 10 days or more after vaccination in the entire trial. We were careful to ascertain that the risk of exposure to Ebola virus and case ascertainment were low and statistically the same in the rings (clusters) that received immediate and delayed vaccination.